New Clinical Trial for Patients Suffering from Frequent Migraine Attacks

Migraine is a neurological condition which is common in the general population and can be severely disabling for the sufferer.​

Migraine can cause multiple symptoms, and is often characterised by intense, debilitating headaches.

Symptoms may include:

  • nausea
  • vomiting
  • difficulty speaking
  • numbness or tingling, and
  • sensitivity to light and sound.

Migraines often run in families and affect all ages.

Tricaprilin is an investigational medicinal product (IMP) that has been developed as an oral formulation for the potential treatment of migraine. ​

To compare how well this study drug works, participants will be randomly assigned to 2 different groups:

  • 75mg IMP twice a day; and
  • placebo twice daily (1:1).

Therefore, all participants have a 1 in 2 chance of receiving the active study drug.

This study will require participation for up to 19 weeks, including 7 on-site visits during that period.

PLEASE NOTE: due to COVID-19 restrictions, there is provision for some visits to be home visits.

Main Inclusion Criteria*:

  • Age 18 to 70 years
  • Clinical diagnosis of migraine with or without aura for at least 1 year
  • Suffer from frequent migraines on a regular basis
  • If receiving medication for migraine, the participant should have been on a stable dose for at least 2 months prior to the screening visit

*​Please note that there are additional criteria that must be met in order to qualify to participate in this study.

Contact NeuroCentrix Research Team
Tell us how to contact you